So let me get this straight....
You contentions are:
1. Startup biotechs on the cusp of clinical trials with their first drug should be cash flow positive? Please provide links to current startup biotech companies that are indeed profitable at the time of filing their first IND. JUST ONE.
2. Filing an IND with the FDA is as simple as "claiming" a new drug. Thats it, nothing else to the process, right? So I could probably write to the FDA today and claim a new drug so that I could pump my company too...? Really>>>???
--BMSN has successfully sought peer review studies and publications for its HemaXellerate I drug.
--BMSN has partnered with several high profile and well respected scientists in the Bio-tech arena such as:
Dr. Vladimir Bogin, CEO of Cromos Pharma
Dr. Thomas Ichim, CEO Medistem
Dr. Ewa Carrier, Associate Professor of Medicine UCSD
Dr. Thomas Ichim, Ph.D
BMSN and Cromos Pharma worked together to ready HemaXellerate I for application to the FDA for the start of clinical trials.
So again, your contention is that BMSN did all of that as part of an elaborate P&D? How did BMSN manage to dupe the well repected scientists listed above into believing in the effectiveness of HemaXellerate I? How did BMSN fool Cromos into believing HemaXellerate I is a real drug with real possibilities?
And above all: if the IND were slapped together as haphazardly as you indicate: would not the FDA have laughed at the application and denied BMSN within days of the filing?
Help me understand how I could be so wrong...
Market Data 
Markets 
AI
